Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Lowering serum urate levels below the threshold for crystal formation with urate-lowering therapy (ULT) has been associated with a lower risk for gout flare reoccurrences. However, gout patients on ULT still commonly suffer from recurring gout flares. The purpose of this study was to explore prognostic factors associated with gout flare recurrence within the first 3 months, in gout patients starting ULT during an acute gout flare. Post-hoc analysis of trial data on acute gout patients randomized to either gout flare standard of care or anakinra treatment were used, including baseline demographic, laboratory, clinical, and patient-reported variables, as well as 3-month follow-up data on gout flare recurrences. Only patients starting ULT at baseline were included. Using variable selection based on clinical relevance, univariate, and multivariate binary logistic regression analyses were done to examine predictors of gout flare reoccurrence. A total of 75 patients were included in this study, of which 36 (48%) experienced a gout flare ≤ 3 months post baseline. The multivariate regression analysis revealed that CRP levels > 30 mg/L (OR 9.47) and lack of prophylaxis when starting ULT (OR 11.56) were independently associated with gout flare recurrence. Similar results were found for the univariate regression analyses. Our results show that CRP levels > 30 mg/L and lack of prophylaxis when starting ULT were prognostic factors for early gout flare reoccurrence in patients starting ULT during an acute gout flare.
• Gout flare recurrences were common within the first 3 months after starting urate-lowering therapy in gout patients.
• Intake of prophylaxis when starting ULT had a strong protective effect on gout flare recurrences.
• C-reactive protein level > 30 mg/L was an additional prognostic factor for early (≤ 3 months) gout flare reoccurrence in patients starting ULT during an acute gout flare.
Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW (2006) Serum urate levels and gout flares analysis from managed care data. J Clin Rheumatol 12:61–65. https://doi.org/10.1097/01.rhu.0000209882.50228.9f CrossRef
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42. https://doi.org/10.1136/annrheumdis-2016-209707 CrossRef
Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald T, Nuki G, Pywell A, Zhang W, Roddy E, British Society for Rheumatology Standards, Audit and Guidelines Working Group (2017) The British Society For Rheumatology guideline for the management of gout. Rheumatology 56:e1–e20. https://doi.org/10.1093/rheumatology/kex150 CrossRef
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of Rheumatology (2012) 2012 American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446. https://doi.org/10.1002/acr.21772 CrossRef
Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, So AK, Bardin T (2012) Gout: why is this curable disease so seldom cured? Ann Rheum Dis 71:1765–1770. https://doi.org/10.1136/annrheumdis-2012-201687 CrossRef
Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D (2012) Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes 10:1–11. https://doi.org/10.1186/1477-7525-10-117 CrossRef
Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA (2011) Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ 14:10–15. https://doi.org/10.3111/13696998.2010.540874 CrossRef
Wortmann RL, MacDonald PA, Hunt B, Jackson RL (2010) Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 32:2386–2397. https://doi.org/10.1016/j.clinthera.2011.01.008 CrossRef
Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR (2009) The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 15:3–7. https://doi.org/10.1097/RHU.0b013e3181945d2c CrossRef
Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, Radovits B, van Durme C, Baan H, van de Laar MAFJ (2019) Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology. https://doi.org/10.1093/rheumatology/key402
Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New York CrossRef
Sundy JS, Schumacher HR, Kivitz A, Weinstein SP, Wu R, King-Davis S, Evans RR (2014) Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 41:1703–1711. https://doi.org/10.3899/jrheum.131226 CrossRef
Schlesinger N, Mysler E, Lin H-Y, de Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A (2011) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 70:1264–1271. https://doi.org/10.1136/ard.2010.144063 CrossRef
Mitha E, Ralph Schumacher H, Fouche L et al (2013) Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatol (United Kingdom) 52:1285–1292. https://doi.org/10.1093/rheumatology/ket114
Schumacher HR, Evans RR, Saag KG et al (2012) Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res 64:1462–1470. https://doi.org/10.1002/acr.21690 CrossRef
Schumacher HR, Sundy JS, Terkeltaub R et al (2012) Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 64:876–884. https://doi.org/10.1002/art.33412 CrossRef
Grainger R, McLaughlin RJ, Harrison AA, Harper JL (2012) Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout. Rheumatol (United Kingdom) 52:1018–1021. https://doi.org/10.1093/rheumatology/kes326
Keenan T, Blaha M, Nasir K et al (2012) Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Am J Cardiol 110:1787–1792. https://doi.org/10.1016/j.amjcard.2012.08.012 CrossRef
Kaplan RC, Frishman WH (2001) Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis 3:326–332. https://doi.org/10.1097/00132580-200109000-00009 CrossRef
Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51:321–325. https://doi.org/10.1002/art.20405 CrossRef
Hunter D, York M, Chaisson C, Woods R, Niu J, Zhang Y (2006) Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 33:1341–1345
Zhang Y, Chen C, Choi H, Chaisson C, Hunter D, Niu J, Neogi T (2012) Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 71:1448–1453. https://doi.org/10.1136/annrheumdis-2011-201215 CrossRef
- Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
C. A. Janssen
M. A. H. Oude Voshaar
P. M. ten Klooster
H. E. Vonkeman
M. A. F. J. van de Laar
- Springer London
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Sommerakademie-Visual, Mail Icon II